Adjusting win statistics for dependent censoring
暂无分享,去创建一个
D. Hoaglin | Duolao Wang | Jiuzhou Wang | J. Verbeeck | Bo Huang | G. Dong | Gaohong Dong
[1] H. Quan,et al. Some Meaningful Weighted Log-Rank and Weighted Win Loss Statistics , 2020 .
[2] D. Hoaglin,et al. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring , 2020, Journal of Biopharmaceutical Statistics.
[3] Lei Peng. The use of the win odds in the design of non-inferiority clinical trials , 2020, Journal of biopharmaceutical statistics.
[4] J. Verbeeck,et al. Evaluation of inferential methods for the net benefit and win ratio statistics , 2020, Journal of biopharmaceutical statistics.
[5] D. Hoaglin,et al. The Win Ratio: On Interpretation and Handling of Ties , 2019, Statistics in Biopharmaceutical Research.
[6] G. Koch,et al. Adjusted win ratio with stratification: Calculation methods and interpretation , 2019, Statistical methods in medical research.
[7] D. Hoaglin,et al. The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards , 2019, Pharmaceutical statistics.
[8] G. Molenberghs,et al. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints , 2019, Statistics in medicine.
[9] S. Pocock,et al. Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[10] M. Ellison,et al. Statistical methods for survival trial design: with applications to cancer clinical trial using R , 2018, Journal of Biopharmaceutical Statistics.
[11] D. Schoenfeld,et al. Graphing the Win Ratio and its components over time , 2018, Statistics in medicine.
[12] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[13] L. Mao,et al. On the alternative hypotheses for the win ratio , 2018, Biometrics.
[14] Jianrong Wu. Statistical Methods for Survival Trial Design , 2018 .
[15] Duolao Wang,et al. The stratified win ratio , 2018, Journal of biopharmaceutical statistics.
[16] M. Hughes,et al. Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms , 2018, Lifetime Data Analysis.
[17] M. Buyse,et al. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring , 2018, Statistical methods in medical research.
[18] M. V. van Noorden,et al. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator , 2018, Statistical methods in medical research.
[19] Xiaodong Luo,et al. Weighted win loss approach for analyzing prioritized outcomes , 2017, Statistics in medicine.
[20] M. Vandemeulebroecke,et al. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components , 2016, Pharmaceutical statistics.
[21] D. Oakes. On the win-ratio statistic in clinical trials with multiple types of event , 2016 .
[22] M. Buyse,et al. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. , 2016, JAMA oncology.
[23] S. Pocock,et al. A win ratio approach to comparing continuous non‐normal outcomes in clinical trials , 2016, Pharmaceutical statistics.
[24] W. Tsai,et al. An alternative approach to confidence interval estimation for the win ratio statistic , 2015, Biometrics.
[25] S. Pocock,et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities , 2011, European heart journal.
[26] M. Buyse. Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem , 2010, Statistics in medicine.
[27] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[28] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.
[29] D. Schoenfeld,et al. Combining mortality and longitudinal measures in clinical trials. , 1999, Statistics in medicine.
[30] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[31] J. Lachin,et al. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. , 2016, Biostatistics.
[32] Salim Yusuf,et al. Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.
[33] M. Pagano,et al. Survival analysis. , 1996, Nutrition.
[34] B. Efron. The two sample problem with censored data , 1967 .